サンプル依頼リスト カート
  • English
  • Korean
表紙：不整脈原性右室心筋症の世界市場-2023年～2030年
市場調査レポート
商品コード
1352171

不整脈原性右室心筋症の世界市場-2023年～2030年

Global Arrhythmogenic Right Ventricular Dysplasia Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
不整脈原性右室心筋症の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の不整脈原性右室心筋症市場は、2022年に9億米ドルに達し、2023-2030年の予測期間中にCAGR 4.3％で成長し、2030年には12億米ドルに達すると予測されます。不整脈原性右室心筋症市場は、遺伝子調査、技術進歩、個別化医療などの要因によって牽引されています。

不整脈原性右室心筋症は、若年層で危険な不整脈を起こす可能性を高める稀な疾患です。この疾患を持つ人の大半は遺伝子変異を持っています。異常な心臓のリズムを起こさないように、医師が薬を処方したり、治療を行ったりするためには、早期の診断と治療が望ましいです。

不整脈原性右室心筋症が重篤な心リズム障害、心不全、あるいは患者の生命に重大な危険をもたらすその他の合併症を引き起こす場合には、治療計画の一部として外科的治療が考慮されます。個々の臨床症状や疾患の重症度に基づいて、不整脈原性右室心筋症に対するさまざまな外科手術が行われます。

増加する研究活動

2022年にCirculation Journalに掲載された論文によると、不整脈原性右室心筋症の治療で最も重要なことの1つは、植込み型除細動器（ICD）の植え込みです。しかし、ICD植え込みの最適な課題を同定し、不整脈リスクを層別化することは、特に心臓突然死の一次予防のためには困難でした。最近，持続性心室性不整脈の既往のない人を対象とした心室性不整脈リスクカリキュレータが提案されました。

このリスクカリキュレータには、不整脈原性右室心筋症患者に頻繁に行われる非侵襲的検査から得られた7つの臨床因子が含まれています。このリスクカリキュレータは独立したコホートにおいて有用であり、現在コンセンサスステートメントで推奨されているリスク層別化アルゴリズムよりも優れていることが証明されています。

不整脈原性右室心筋症の管理の増加

不整脈原性右室心筋症（ARVD）の管理と認知の開拓は、ARVD世界市場の発展に寄与する可能性があります。疾患管理の改善は、ARVD市場の成長を促進する重要な戦略の1つです。ARVDの遺伝的基盤がよりよく理解されれば、より専門的な治療計画が可能になります。

特定の患者の遺伝子プロファイルに治療法を適合させることで、治療効果を高め、潜在的な副作用を減らすことができます。ARVDに対する認識が高まることで、この疾患に対する関心が高まり、投資が促進され、特にこの疾患を標的とした新規の治療戦略、薬剤、医療機器の開発に拍車がかかる可能性があります。

不整脈原性右室心筋症診断に伴う課題

不整脈原性右室心筋症は、様々な試みにもかかわらず、未だ不明な点が多く、診断の遅れや不正確さの原因となり、患者が適切な治療を受けることを妨げています。より一般的な疾患と比較して、不整脈源性右室形成異常はその稀少性から、研究資金や注目を集めることができませんでした。

加えて、不整脈原性右室心筋症は遺伝的で多様な疾患であるため、効果的な治療法を開発することは困難であり、"万能"のアプローチを見つけることは困難です。さらに、参加者のリクルートが困難であり、特殊な知識が必要とされるため、希少疾患の臨床試験を実施するには高額な費用が必要となります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 不整脈原性右室心筋症の管理増加
    • 抑制要因
      • 不整脈原性右室心筋症の診断に伴う課題
    • 機会
      • 技術の進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • パイプライン分析
  • 価格分析
  • アンメットニーズ

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 治療別

  • 外科治療
    • 植込み型除細動器（ICD）
    • 補助人工心臓（VAD）
    • ペースメーカー
    • 中隔切除術
    • 心臓移植
    • その他
  • 手術以外
    • 中隔アブレーション
    • ラジオ波焼灼術
    • 薬剤

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 画像診断センター
  • 外来手術センター
  • 学術研究機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第13章 企業プロファイル

  • Centogene AG
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Ambry Genetics.
  • GeneDx.
  • Illumina Inc.
  • Asper Biogene.
  • Cohesion Phenomics
  • Blueprint Genetics Oy
  • Aetna Inc
  • Invitae Corporation
  • Medanta

第14章 付録

目次
Product Code: PH3157

Overview

The Global Arrhythmogenic Right Ventricular Dysplasia Market reached US$ 0.9 billion in 2022 and is expected to reach US$ 1.2 billion by 2030 growing with a CAGR of 4.3% during the forecast period 2023-2030. The arrhythmogenic right ventricular dysplasia market is driven by factors such as genetic research, technological advancements, and personalized medicine.

Arrhythmogenic right ventricular dysplasia is a rare disorder that raises the possibility of dangerously irregular heartbeats in young people. The majority of those who have this condition have a genetic mutation. It is preferable to receive early diagnosis and treatment so that doctors can prescribe medications and perform treatments to help patients prevent having abnormal heart rhythms.

Surgical treatments are taken into consideration as part of the treatment plan when arrhythmogenic right ventricular dysplasia causes serious heart rhythm problems, heart failure, or other complications that pose a serious risk to the patient's life. Based on the individual clinical presentation and severity of the disease, different surgical procedures for arrhythmogenic right ventricular dysplasia are used.

The Increasing Research Activities

As per the article published in Circulation Journal in 2022, one of the most important aspects of treating Arrhythmogenic right ventricular cardiomyopathy is the implantation of an implanted cardioverter defibrillator (ICD). However, it has been challenging to identify the best candidates for ICD installation and to stratify arrhythmic risk, particularly for the primary prevention of sudden cardiac death. Recently, a ventricular arrhythmias risk calculator for people without a history of sustained ventricular arrhythmias was suggested.

Seven clinical factors from noninvasive tests that are frequently carried out on patients with Arrhythmogenic right ventricular cardiomyopathy were included in this risk calculator. It has been demonstrated to be useful in independent cohorts and to outperform risk stratification algorithms currently recommended by consensus statements.

Increasing Management of the Arrhythmogenic Right Ventricular Dysplasia

Growing management and awareness of Arrhythmogenic Right Ventricular Dysplasia (ARVD) may benefit the development of the global ARVD market. Improved disease management is one of the key strategies that can promote the ARVD market's growth. The genetic underpinnings of ARVD can be better understood to enable more specialized treatment plans.

Treatment efficacy can be increased and potential side effects can be decreased by adapting therapies to the genetic profiles of such specific patients. Growing awareness of ARVD may increase interest in the subject and encourage investment, which could spur the development of novel therapy strategies, drugs, and medical devices that particularly target the condition.

Challenges Associated with Arrhythmogenic Right Ventricular Dysplasia Diagnosis

Despite attempts, arrhythmogenic right ventricular dysplasia is still largely unknown, which causes delayed or inaccurate diagnoses and prevents patients from receiving the right care. Compared to illnesses that are more common, arrhythmogenic right ventricular dysplasia could not attract as much funding or attention for study because of its rarity.

In addition, due to the genetic and diverse character of arrhythmogenic right ventricular dysplasia, developing effective treatments can be challenging and it is challenging to find a "one-size-fits-all" approach. Moreover, because of the difficulty in recruiting participants and the specific knowledge needed, conducting clinical trials for a rare condition can be expensive.

Segment Analysis

The global arrhythmogenic right ventricular dysplasia market is segmented based on treatment, end-user and region.

The Surgical Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The surgical segment accounted for the highest market stake accounting for approximately 3/5th of the arrhythmogenic right ventricular dysplasia market in 2022. Surgical treatments may be taken into consideration as part of the treatment plan when arrhythmogenic right ventricular dysplasia causes serious heart rhythm problems, heart failure, and other complications that pose a serious risk to the patient's life. Depending on the exact clinical presentation and severity of the disease, different surgical methods for arrhythmogenic right ventricular dysplasia can be used.

Patients with arrhythmogenic right ventricular dysplasia who are at risk of experiencing life-threatening arrhythmias can have surgery to implant an Implantable Cardioverter-Defibrillator (ICD). In a risky arrhythmia situation, an ICD device is implanted that monitors the heart's rhythm and administers electrical shocks to restore normal rhythm.

Some arrhythmogenic right ventricular dysplasia patients have recurrent ventricular tachycardia, a rapid heartbeat that comes from the ventricles. Catheters are used during ablation operations to locate and remove the aberrant heart tissue that is the source of the arrhythmia.

Geographical Penetration

North America Holds a Dominant Position in the Global Arrhythmogenic Right Ventricular Dysplasia Market

North America is estimated to hold around 45.0% of the total market share throughout the forecast period. Number of driving factors in North America helps in knowing the arrhythmogenic right ventricular dysplasia treatment which is recognized, diagnosed, and treated. With access to cutting-edge diagnostic equipment, specialized medical facilities, and trained healthcare staff, North America has a sophisticated healthcare infrastructure.

This makes it easier to diagnose arrhythmogenic right ventricular dysplasia quickly and accurately, which enables prompt treatment. The region is a center for medical innovation and research. There is a lot of information and developments in the field of cardiovascular medicine, including arrhythmogenic right ventricular dysplasia, due to universities, research facilities, and medical facilities.

Competitive Landscape

The major global players in the market include: Centogene AG, Ambry Genetics, GeneDx., Illumina Inc., Asper Biogene., Cohesion Phenomics, Blueprint Genetics Oy, Aetna Inc, Invitae Corporation, and Medanta among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the arrhythmogenic right ventricular dysplasia market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Healthcare services may be disrupted by violence, making it difficult for patients to get the treatment, diagnosis, and care they need. The prompt detection and treatment of illnesses like arrhythmogenic right ventricular dysplasia may be impacted by this disturbance.

Conflict can put a strain on the healthcare system because resources was redirected to treating war-related injuries and providing emergency treatment. The ability to deliver specialist care for illnesses like arrhythmogenic right ventricular dysplasia impacted by this strain.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the arrhythmogenic right ventricular dysplasia market to improve various aspects of diagnostics. Healthcare practitioners can use AI algorithms to help them analyze cardiac imaging data from cardiac MRI or CT scans to find modest structural anomalies linked to arrhythmogenic right ventricular dysplasia. AI can assist in spotting disease-related trends and offer more precise and reliable diagnoses.

Furthermore, AI can assist in the processing of genetic data, making it easier to pinpoint specific mutations linked to arrhythmogenic right ventricular dysplasia. If someone has a genetic susceptibility to the illness, this can help with early detection and risk assessment.

By Treatment

  • Surgical
    • Implantable Cardioverter Defibrillator (ICD)
    • Ventricular Assist Device (VAD)
    • Pacemaker
    • Septal Myectomy
    • Heart Transplant
    • Others
  • Non-Surgical
    • Septal Ablation
    • Radiofrequency Ablation Liver Transplantation
    • Drugs

By End-user

  • Hospitals
  • Specialty Clinics
  • Diagnostics Imaging Center
  • Ambulatory Surgery Center
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In November 2022, Tenaya Therapeutics, a clinical-stage biotechnology company declared that the U.S. Food and Drug Administration granted orphan drug designation for its second gene therapy product candidate, TN-401, for the therapy of arrhythmogenic right ventricular cardiomyopathy.

Why Purchase the Report?

  • To visualize the global arrhythmogenic right ventricular dysplasia market segmentation based on the treatment, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of arrhythmogenic right ventricular dysplasia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of critical products of all the major players.

The global arrhythmogenic right ventricular dysplasia market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by End-user
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising management of arrhythmogenic right ventricular dysplasia
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with arrhythmogenic right ventricular dysplasia diagnosis
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pipeline Analysis
  • 5.5. Pricing Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment
  • 9.2. Surgical*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Implantable Cardioverter Defibrillator (ICD)
    • 9.2.4. Ventricular Assist Device (VAD)
    • 9.2.5. Pacemaker
    • 9.2.6. Septal Myectomy
    • 9.2.7. Heart Transplant
    • 9.2.8. Others
  • 9.3. Non-Surgical
    • 9.3.1. Septal Ablation
    • 9.3.2. Radiofrequency Ablation
    • 9.3.3. Drugs

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.1.2. Market Attractiveness Index, By End-user
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Diagnostics Imaging Center
  • 10.5. Ambulatory Surgery Center
  • 10.6. Academic and Research Institutes
  • 10.7. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.5.1. U.S.
      • 11.2.5.2. Canada
      • 11.2.5.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. U.K.
      • 11.3.5.3. France
      • 11.3.5.4. Italy
      • 11.3.5.5. Spain
      • 11.3.5.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Brazil
      • 11.4.5.2. Argentina
      • 11.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. Australia
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. Centogene AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Ambry Genetics.
  • 13.3. GeneDx.
  • 13.4. Illumina Inc.
  • 13.5. Asper Biogene.
  • 13.6. Cohesion Phenomics
  • 13.7. Blueprint Genetics Oy
  • 13.8. Aetna Inc
  • 13.9. Invitae Corporation
  • 13.10. Medanta

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us